Tirzepatide is a synthetic dual incretin-receptor agonist — a single peptide molecule engineered to engage two G-protein-coupled receptors simultaneously: the GLP-1 receptor (target of the established GLP-1 agonist class) and the GIP receptor, with the GIP arm exhibiting biased agonism. Studied across type 2 diabetes, obesity, MASH, and cardiovascular-outcome clinical trial programs (SURPASS, SURMOUNT).
Definition
Tirzepatide is a 39-amino-acid synthetic peptide engineered to act as a co-agonist at two distinct incretin-hormone receptors simultaneously. The two receptor targets are the receptor for glucose-dependent insulinotropic polypeptide (the GIP receptor) and the receptor for glucagon-like peptide 1 (the GLP-1 receptor). The molecule was designed by Eli Lilly to incorporate sequence elements from both native incretin hormones along with a fatty-acid sidechain that supports albumin binding and once-weekly subcutaneous dosing through extended plasma half-life. Pharmacological characterisation establishes the compound as a biased agonist — the GIP receptor engagement is conformationally distinct from native GIP and produces a different downstream signalling profile (PMID 32730231).
The compound is FDA-approved for type 2 diabetes and chronic weight management in adults with obesity. The dual-receptor mechanism produces glycemic and weight-reduction effects that exceed monotherapy with single-receptor GLP-1 agonists in head-to-head comparison.
How tirzepatide is studied in research and clinical literature
The tirzepatide clinical-trial program is among the largest peptide-therapeutic studies of the early 2020s. The SURPASS program established efficacy and safety in type 2 diabetes against multiple comparators (SURPASS-4 vs insulin glargine, PMID 34672967; SURPASS-5 vs placebo added to insulin, PMID 35133415). Direct head-to-head against semaglutide in type 2 diabetes was published in Frías and colleagues (PMID 34170647). Effects on liver fat and abdominal adipose tissue were characterised in the SURPASS-3 MRI substudy (PMID 35468325). The SURMOUNT program extended the framing into obesity without diabetes (SURMOUNT-2, PMID 37385275; SURMOUNT-4 weight-maintenance, PMID 38078870; SURMOUNT-CN Chinese population, PMID 38819983).
Mechanistic and beta-cell-function characterisation work was published in the Thomas study documenting improvements in beta-cell function and insulin sensitivity (PMID 33236115). Recent extensions cover obstructive sleep apnea (PMID 38912654), MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis (PMID 38856224), and systematic-review/network-meta-analysis comparison against semaglutide (PMID 38613667). Comprehensive reviews consolidate the dataset for clinical-pharmacology context (PMID 36050763, PMID 38388874).
Related terms
- Semaglutide
- GIP (glucose-dependent insulinotropic polypeptide)
- GLP-1 (glucagon-like peptide 1)
- Dual receptor agonist
- Biased agonism
- Incretin hormone
Where tirzepatide appears in the Ronin catalog
- Tirzepatide 10mg — single-compound vial, lyophilized white powder under inert gas; research use only
References
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5(17):e140532. [PMID 32730231]
- Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab 2021;106(2):388-396. [PMID 33236115]
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385(6):503-515. [PMID 34170647]
- Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet 2021;398(10313):1811-1824. [PMID 34672967]
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023;402(10402):613-626. [PMID 37385275]
- Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 2024;391(4):299-310. [PMID 38856224]
Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Tirzepatide is sold strictly as a research-grade reagent for laboratory and bench research applications.